首页> 外文期刊>The Journal of Physiology >Decline in cellular function of aged mouse c-kit(+) cardiac progenitor cells
【24h】

Decline in cellular function of aged mouse c-kit(+) cardiac progenitor cells

机译:老年小鼠C-kit(+)心脏祖细胞细胞功能下降

获取原文
获取原文并翻译 | 示例
           

摘要

Therapeutic use of c-kit(+) cardiac progenitor cells (CPCs) is being evaluated for regenerative therapy in older patients with ischaemic heart failure. Our understanding of the biology of these CPCs has, however, largely come from studies of young cells and animal models. In the present study we examined characteristics of CPCs isolated from young (3 months) and aged (24 months) mice that could underlie the diverse outcomes reported for CPC-based therapeutics. We observed morphological differences and altered senescence indicated by increased senescence-associated markers -galactosidase and p16 mRNA in aged CPCs. The aged CPCs also proliferated more slowly than their young counterparts and expressed lower levels of the stemness marker LIN28. We subsequently treated the cells with dexamethasone (Dex), routinely used to induce commitment in CPCs, for 7 days and analysed expression of cardiac lineage marker genes. While MEF2C, GATA4, GATA6 and PECAM mRNAs were significantly upregulated in response to Dex treatment in young CPCs, their expression was not increased in aged CPCs. Interestingly, Dex treatment of aged CPCs also failed to increase mitochondrial biogenesis and expression of the mitochondrial proteins Complex III and IV, consistent with a defect in mitochondria complex assembly in the aged CPCs. Dex-treated aged CPCs also had impaired ability to upregulate expression of paracrine factor genes and the conditioned media from these cells had reduced ability to induce angiogenesis in vitro. These findings could impact the design of future CPC-based therapeutic approaches for the treatment of older patients suffering from cardiac injury.
机译:正在评估C-kit(+)心脏祖细胞(CPC)的治疗使用,用于缺血性心力衰竭患者的再生治疗。然而,我们对这些CPC的生物学的理解,很大程度上来自对年轻细胞和动物模型的研究。在本研究中,我们检查了从年轻(3个月)和年龄(24个月)小鼠中分离的CPC的特征,这可能使CPC的疗法据报道的不同成果提出。我们观察到通过增加的CPC中的衰老相关标记物增加和P16 mRNA增加的形态学差异和改变的衰老。老年的CPC也比其年轻对应物慢得多,表达了茎秆标志物LIN28的较低水平。随后我们用地塞米松(DEX)对细胞进行了处理,常规用于诱导CPC的承诺7天并分析心脏谱系标记基因的表达。虽然MEF2C,GATA4,GATA6和PECAM MRNA在响应于年轻CPC中的DEX治疗时显着上调,但在老年的CPC中,它们的表达不会增加。有趣的是,老年人CPC的DEX治疗也未能提高线粒体生物发生和线粒体蛋白质复合物III和IV的表达,其与老化CPC中的线粒体复合组件的缺陷一致。 Dex治疗的老年CPC也损害了上调旁静脉因子基因的表达和来自这些细胞的调节培养基的能力减轻了在体外诱导血管生成的能力。这些发现可能影响未来基于CPC的治疗方法的设计,以治疗患有心损伤的老年患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号